Shareholder Alert: Ademi LLP investigates whether Sigilon Therapeutics, Inc. has obtained a Fair Price in its transaction with Eli Lilly

Provided By PR Newswire

Last update: Jun 29, 2023

MILWAUKEE, June 29, 2023 /PRNewswire/ -- Ademi LLP is investigating Sigilon (Nasdaq: SGTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Eli Lilly.